|
(Health-NewsWire.Net, August 03, 2020 ) The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years. The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.
MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period.
Among the product & service, segment, the reagents and kits segment is expected to grow at the highest CAGR during the forecast period. The factors attributing to the high growth are, the accessibility of a wide range of reagents, the increasing demand for reagents owing to the increasing genotyping test volumes across the globe, and the relatively smaller capital investment required to adopt reagents and kits for genotyping in pharmaceuticals and diagnostic centers.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595
Global Genotyping Assay Market is Segmented on:
1. Technology
2. Application
3. Product
The pharmaceutical and biopharmaceutical companies segment is expected to witness the highest growth during the forecast period. The increasing demand for pharmacogenomics in the drug discovery and development process and recommendations from the FDA to include genotyping and pharmacogenomics studies in the course of drug discovery have contributed to the growth of this market segment.
On the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment is expected to account for the largest share of the genotyping market during the forecast period. The large share of this segment can be attributed to the increasing use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595
The geographical regions mapped in the report are:
North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.
Some key players mentioned in the research report are:
Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
